Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. - Cohen, E. E. W.; Licitra, L. F.; Burtness, B.; Fayette, J.; Gauler, T.; Clement, P. M.; Grau, J. J.; del Campo, J. M.; Mailliez, A.; Haddad, R. I.; Vermorken, J. B.; Tahara, M.; et al. (Annals of Oncology, 2017)